Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye infection breakthrough: new trial tests antivirals to save sight

NCT ID NCT03586284

Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two antiviral medicines (oral valganciclovir and topical ganciclovir 2%) against a placebo for treating CMV-related inflammation in the front of the eye. The goal was to see which approach better controls the infection and reduces complications like pain, glaucoma, and vision loss. The trial enrolled 51 adults with confirmed CMV anterior uveitis and measured changes in viral load and eye inflammation over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

51 people

The number who actually took part.

Started

Mar 2020

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical impression consistent with CMV anterior uveitis * Directed PCR positive for CMV OR previous PCR-proven CMV anterior uveitis * Willingness to use an acceptable method of contraception during the study period (i.e. pharmacologic, devices, barrier methods) or abstinence. Exclusion Criteria: * Patients \<18 years of age * Intermediate or posterior inflammation (involvement of vitreous, choroid, or retina) * Received antiviral therapy \<14 days prior to enrollment * Received periocular or intraocular corticosteroid injection \< 8 weeks prior to enrollment * Currently taking oral corticosteroids * Immunocompromised (primary or secondary immunosuppressive disorders) * Prior immunosuppressive therapy in the past 6 months * Directed PCR negative for CMV * Directed PCR positive for herpes simplex virus (HSV) or varicella zoster virus (VZV) * Planning to conceive during the study period, pregnant or breast-feeding (blood or urine pregnancy test for all females of child-bearing age is mandatory within 4 weeks prior to enrollment) * Complete blood count with white blood cell, absolute neutrophil, or platelet count lower than the lower limit of reference laboratory normal * BUN or Cr above the upper limit of reference laboratory normal * Recent ocular surgery within the past 30 days, or planned surgery within the next 45 days * Systemic autoimmune disease or ocular condition (besides anterior uveitis) anticipated to dictate or alter treatment course

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus anterior uveitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious anterior uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus anterior uveitis

Contacts and locations

Locations

  • Chiang Mai University

    Chiang Mai, Thailand

  • Chulalongkorn University

    Bangkok, Thailand

  • Khon Kaen University

    Khon Kaen, Thailand

  • Proctor Foundation, UCSF

    San Francisco, California, 94158, United States